Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells
Open accessThe DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Abstract
Even though various treatment methods are available for cancer, the death curve is not reducing. The diagnosis of cancer at the fourth stage and drug resistance are the leading reasons for treatment failure and lower survival rates. In this review article, we summarize the possible pitfalls during cancer treatment in general, which mainly include multidrug resistance, and propose a hypothesis for colorectal cancer specifically. We also evaluate multidrug resistance in cancer in general and colorectal cancer in particular and hypothesize a concept based on combination therapy with 5-fluorouracil, curcumin, and lipids for the possible management of colorectal cancer. In addition, a hypothetical approach, combining a synthetic agent and a natural chemotherapeutic agent, to treating colorectal cancer is also discussed. This hypothesis could improve the management of colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Overexpression of ABC transporters is thought to be the main cause of MDR in cancer cells [45].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, defective apoptotic pathways can contribute to MDR [45].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Multiple strategies with the synergistic approach for addressing colorectal cancer
Karthika, C., Hari, B., Rahman, M. H., Akter, R., Najda, A., Albadrani, G. M., Sayed, A. A., Akhtar, M. F., & Abdel‐Daim, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111704 · Cited by 43 · cited 1×
“When colorectal cancer is detected in its early stages, surgery is the most commonly used treatment [65].”
BackgroundSelf-citationRetractedEngineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933 · cited 1×
“Because lipid-based drug delivery travels through the lymphatic system, including lipids in this combination [73] can help with cancer cell targeting and even treatment during the metastatic stage [74].”
BackgroundThe blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C. D., Ferraro, G. B., & Jain, R. K. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,792 · cited 2×
“the body where the drug cannot be accessed or the tumor comprises compromised vasculature [43].”
BackgroundMechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757 · cited 1×
“P-gp is the main reason for MDR in cancer cells [76].”
BackgroundTargeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097 · cited 1×
“Even though these are the major differences between MRP and MDR1 P-gp in the drugs that they transport or interact with, the drugs on which these two proteins act are varied, and the inhibitors that modify their activities are also different [52].”
BackgroundSawicki, T., Ruszkowska, M., Danielewicz, A., Niedźwiedzka, E., Arłukowicz, T., & Przybyłowicz, K. E. (2021) · Cancers · doi:10.3390/cancers13092025 · Cited by 921 · cited 1×
“Although the precise causes of colorectal cancer are indefinite, experts believe that diet plays an important role [6].”
BackgroundTherapeutic Potential of Quercetin: New Insights and Perspectives for Human Health
Salehi, B., Machin, L., Monzote, L., Sharifi-Rad, J., Ezzat, S. M., Salem, M. A., Merghany, R. M., El Mahdy, N. M., Kılıç, C. S., Sytar, O., et al. (2020) · ACS Omega · doi:10.1021/acsomega.0c01818 · Cited by 707 · cited 1×
“Because flavonoids have a synergistic effect on cancer cells [94], our anticipated formulation will reduce the drug’s dosing frequency even further [95].”
BackgroundGlobal cancer incidence in older adults, 2012 and 2035: A population‐based study
Pilleron, S., Sarfati, D., Janssen‐Heijnen, M., Vignat, J., Ferlay, J., Bray, F., & Soerjomataram, I. (2019) · International Journal of Cancer · doi:10.1002/ijc.31664 · Cited by 670 · cited 1×
“This figure is predicted to rise to 24 million by 2035 [5].”
BackgroundZebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567 · cited 1×
“This mechanism has been studied in considerable detail and has enabled the development of an understanding of how drugs are handled in the body, based on how cancer cells handle these drugs [18].”
BackgroundThe multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528 · cited 1×
“1980s: Multidrug resistance was shown, in most cases, to result from decreased intercellular drug accumulation, apparently as a result of alterations in the plasma membrane [28].”
Background
Research works printed but not linked: 4
- Sosnik, A., and Bendayan, R. (2019). Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy, Academic Press.
- Power, J.F. (2018). The Role of Extracellular Vesicles in the Transfer of Multidrug Resistance in Human Ovarian Cancer Cells. [Master’s Thesis, Queen’s University].
- Ahmed, A.H. (2021). Identifying Anti-Cancer Drugs Targeting ALK Inhibitors with P-Glycoprotein and Studying It’s Molecular Mechanism of Transport. [Ph.D. Thesis, University of Georgia].
- Zargan, 2022, Evaluation of the Anti-Cancer Effect of Curcumin on MCF-7 Cells in 3D Culture Conditions to Increase the Efficacy of Breast Cancer Treatment, J. Appl. Biotechnol. Rep., 9, 547
Cited by
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
Ashique, S., Bhowmick, M., Pal, R., Khatoon, H., Kumar, P., Sharma, H., Garg, A., Kumar, S., & Das, U. (2024) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2024.100114 · Cited by 139
Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein
Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Tagde, P., Ahmed, Z., Khan, F. S., et al. (2022) · Life · doi:10.3390/life12060897 · Cited by 181
“Modifying P-gp function using various inducers, inhibitors, or genetic polymorphisms is a common strategy [110].”
BackgroundSelf-citationMechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Furthermore, defective apoptotic pathways can contribute to MDR [45].”
New insights into targeted therapy of glioblastoma using smart nanoparticles
Ghaznavi, H., Afzalipour, R., Khoei, S., Sargazi, S., Shirvalilou, S., & Sheervalilou, R. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03331-3 · Cited by 56
“Another major barrier against the efficacy of anticancer treatment is MDR [95].”
BackgroundPhytocompounds and Nanoformulations for Anticancer Therapy: A Review
Bozzuto, G., Calcabrini, A., Colone, M., Condello, M., Dupuis, M. L., Pellegrini, E., & Stringaro, A. (2024) · Molecules · doi:10.3390/molecules29163784 · Cited by 46
“However, the effectiveness of therapy is very often limited by the onset of drug resistance due to epigenetic factors, changes in drug metabolism, increases in drug efflux mediated by ATP-binding cassette transporters, increased DNA repair, and autophagy induction [89].”
Background
Metadata
- Authors
- Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Kundu, M. K., Dey, A., Rahman, M. H., Antonescu, A., & Cavalu, S.
- Affiliations
- JSS Academy of Higher Education and Research (IN)
- Prince Sattam Bin Abdulaziz University (SA)
- Yonsei University (KR)
- Department of Licensing and Enforcement, Laboratory Services, Botswana Medicines Regulatory Authority (BoMRA), Gaborone 999106, Botswana
- R. P. Shaha University (BD)
- Khulna University (BD)
- Presidency University (IN)
- University of Oradea (RO)
- Corresponding author
- Sureshkumar, Raman
- Rahman, Md. Habibur
- Cavalu, Simona
- ORCID
- Venue
- Life
- Publisher
- MDPI AG
- Published
- 2022-05-30
- Volume
- 12
- Issue
- 6
- Pages
- 811
- ISSN
- 2075-1729 (ISSN-L)
- PMC
- PMC9224881
- OpenAlex
- W4281679094
- Cited by
- 30
- References
- 94
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 6 · 2022: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Life (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Department of Science and Technology, Ministry of Science and Technology, India
- Indian Council of Medical Research
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- multidrug resistance, colorectal cancer, combination therapy, 5-fluorouracil, curcumin, lipids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells. https://app.cochat.ai/papers/10.3390/life12060811
- The paper
- Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Kundu, M. K., Dey, A., Rahman, M. H., Antonescu, A., & Cavalu, S. (2022). Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells. Life. https://doi.org/10.3390/life12060811
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.